Condition: Myeloma Multiple · Plasma Cell Leukemia · AL Amyloidosis · Sponsor: St. Olavs Hospital
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.
This description comes directly from the study's public registry record.
Tobias S Slørdahl, MD PhD · +4772825100 · tobias.s.slordahl@ntnu.no
Juni S Paulsen, MD · +4772825100 · juni.paulsen@ntnu.no
Always discuss trial participation with your own doctor first.
| Sørlandet Hospital - Arendal | Arendal, Norway | Not Yet Recruiting |
| Ålesund hospital, Department of hematology | Ålesund, Norway | Not Yet Recruiting |
| Haukeland University Hospital | Bergen, Norway | Not Yet Recruiting |
| Bodø Hospital | Bodø, Norway | Not Yet Recruiting |
| Bærum Hospital | Bærum, Norway | Not Yet Recruiting |
| Drammen hospital | Drammen, Norway | Not Yet Recruiting |
| Førde hospital | Førde, Norway | Not Yet Recruiting |
| Innlandet hospital trust | Gjøvik, Norway | Not Yet Recruiting |
| Haugesund hospital | Haugesund, Norway | Not Yet Recruiting |
| Sørlandet hospital | Kristiansand, Norway | Not Yet Recruiting |
| Nordmøre and Romsdal Hospital - Kristiansund | Kristiansund, Norway | Not Yet Recruiting |
| Levanger hospital | Levanger, Norway | Not Yet Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06855121